Next Article in Journal
DNA Damage, Mutagenesis and Cancer
Next Article in Special Issue
GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance
Previous Article in Journal
Protective Effects of Gomisin N against Hepatic Cannabinoid Type 1 Receptor-Induced Insulin Resistance and Gluconeogenesis
Previous Article in Special Issue
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(4), 969;

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway
Genomics Core Facility, Department of Core facility, Institute for Cancer Research, Oslo University Hospital, 0379 Oslo, Norway
Department of Clinical Science, University of Bergen, Bergen, Norway
Authors contributed equally.
Authors to whom correspondence should be addressed.
Received: 15 February 2018 / Revised: 9 March 2018 / Accepted: 22 March 2018 / Published: 23 March 2018
(This article belongs to the Special Issue Current Advances in Soft Tissue and Bone Sarcoma)
Full-Text   |   PDF [4301 KB, uploaded 3 May 2018]   |  


The BRAFV600E mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAFV600E mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (A673) and atypical synovial sarcoma (SW982), were treated with vemurafenib and the effects on cell growth, apoptosis, cell cycle progression and cell signaling were determined. Results: Vemurafenib induced a strong cytostatic effect in SA-4 cells, mainly due to cell cycle arrest, whereas only moderate levels of apoptosis were observed. However, a high dose was required compared to BRAFV600E mutated melanoma cells, and removal of vemurafenib demonstrated that the continuous presence of drug was required for sustained growth inhibition. A limited growth inhibition was observed in the other three cell lines. Protein analyses demonstrated reduced phosphorylation of ERK during treatment with vemurafenib in all the four sarcoma cell lines confirming that the MAPK pathway is active in these cell lines, and that the pathway can be inhibited by vemurafenib, but also that these cells can proliferate despite this. Conclusions: These findings indicate that vemurafenib alone would not be an efficient therapy against BRAFV600E mutated sarcomas. However, further investigations of combination with other drugs are warranted. View Full-Text
Keywords: BRAF; precision medicine; drug repurposing BRAF; precision medicine; drug repurposing

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Gouravan, S.; Meza-Zepeda, L.A.; Myklebost, O.; Stratford, E.W.; Munthe, E. Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. Int. J. Mol. Sci. 2018, 19, 969.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top